Bristol-Myers Squibb And Pfizer Provide Update On Apixaban Clinical Development Program Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program today. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).
Source: www.medicalnewstoday.comPotential New Targets For Antidepressant Medications The news about antidepressant medications over the past several years has been mixed. The bad news from large multicenter studies such as STAR*D is that current antidepressant medications are effective, but not as effective as one might hope. Thus, there is a significant need for new treatment mechanisms for depression. On that front, there has been mixed news as well.
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
